Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Does Plasma Volume Replacement With 5% Human Albumin Reduce Endothelial Injury and Glycocalyceal Disruption Compared With 6% Hydroxyethylstarch (130/0.4) in Patients Having Cardiac Surgery? A Substudy of the SHARP Clinical Trial

NCT02882074 is registered in ClinicalTrials.gov with The Cleveland Clinic as lead sponsor.

NCT NCT02882074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02882074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Does Plasma Volume Replacement With 5% Human Albumin Reduce Endothelial Injury and Glycocalyceal Disruption Compared With 6% Hydroxyethylstarch (130/0.4) in Patients Having Cardiac Surgery? A Substudy of the SHARP Clinical Trial
Lead sponsor
The Cleveland Clinic
Phase
Not applicable
Overall status
Completed
Start date
June 30, 2016
Completion date
February 20, 2020
Enrollment
85 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

endothelial dysfunction